{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:08:44Z","timestamp":1776276524370,"version":"3.50.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,9,23]],"date-time":"2017-09-23T00:00:00Z","timestamp":1506124800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s40259-017-0246-1","type":"journal-article","created":{"date-parts":[[2017,9,23]],"date-time":"2017-09-23T01:49:39Z","timestamp":1506131379000},"page":"555-558","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["GP2015: An Etanercept Biosimilar"],"prefix":"10.1007","volume":"31","author":[{"given":"Emma D.","family":"Deeks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,23]]},"reference":[{"key":"246_CR1","unstructured":"Sandoz GmbH. Erelzi: EU summary of product characteristics. 2017. \n                        http:\/\/www.ema.europa.eu\n                        \n                    . Accessed 15 Sept 2017."},{"issue":"6","key":"246_CR2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/03007995.2017.1288612","volume":"33","author":"V Strand","year":"2017","unstructured":"Strand V, Girolomoni G, Schiestl M, et al. The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar. Curr Med Res Opin. 2017;33(6):993\u20131003.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"246_CR3","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/14712598.2016.1217329","volume":"16","author":"HP Hofmann","year":"2016","unstructured":"Hofmann HP, Kronthaler U, Fritsch C, et al. Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel\u00ae). Expert Opin Biol Ther. 2016;16(10):1185\u201395.","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"246_CR4","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/bcp.13170","volume":"83","author":"O Richter von","year":"2017","unstructured":"von Richter O, Skerjanec A, Afonso M, et al. GP2015, a proposed etanercept biosimilar: pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes. Br J Clin Pharmacol. 2017;83(4):732\u201341.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"246_CR5","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/bjd.15152","volume":"176","author":"CEM Griffiths","year":"2017","unstructured":"Griffiths CEM, Thaci D, Gerdes S, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2017;176(4):928\u201338.","journal-title":"Br J Dermatol"},{"key":"246_CR6","doi-asserted-by":"crossref","unstructured":"Ruff L, Rezk MF, Uhlig T, et al. Budget impact analysis of an etanercept biosimilar for the treatment of all licensed etanercept indications for adults in Europe [abstract no. PMS33]. Value Health. 2015;18:A639.","DOI":"10.1016\/j.jval.2015.09.2278"},{"key":"246_CR7","doi-asserted-by":"crossref","unstructured":"Bhattacharyya S, Banerjee S, Clinton H, et al. Impact of etanercept biosimilar launches on healthcare spending: a UK budget impact model for the treatment of rheumatoid arthritis and chronic plaque psoriasis [abstract no. PSY35]. Value Health. 2016;19(7):A580\u20131.","DOI":"10.1016\/j.jval.2016.09.1350"}],"updated-by":[{"DOI":"10.1007\/s40259-018-0296-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000}}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-017-0246-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-017-0246-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-017-0246-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T08:32:04Z","timestamp":1533285124000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-017-0246-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,23]]},"references-count":7,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["246"],"URL":"https:\/\/doi.org\/10.1007\/s40259-017-0246-1","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40259-018-0296-z","asserted-by":"object"}]},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,23]]}}}